Background: Patients with pre‐existing severe cardiovascular comorbidities are often deemed ineligible for potentially life‐saving thoracic surgeries and are referred to other conservative therapies. However, this patient population may theoretically benefit from the timely perioperative implantation of temporary mechanical circulation support (tMCS) to both mitigate the surgical stress and stabilize hemodynamics. We performed a scoping review to summarize the evidence regarding the use of tMCS in thoracic surgery.Methods: We conducted a systematic search across PubMed/MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Web of Science, Scopus, and Google Scholar from their inception, aided by a search string encompassing a combination of terms for the key research concepts: i) tMCS devices; ii) thoracic surgery procedures (except lung transplantation); and iii) the adult population.Results: Fifteen studies pertinent to the research question, which summarized data from 28 patients, were retrieved for inclusion. In 14 patients, tMCS implantation occurred as a “pre‐emptive” strategy, while the remaining patients had tMCS implanted either intra and/or postoperatively as a “bail‐out” strategy. Specifically, 14 patients required an intra‐aortic balloon pump, 10 veno‐arterial extracorporeal membrane oxygenation, two required a multidevice strategy, and one cardiopulmonary bypass. The relative risk analysis revealed that the mortality rate in the pre‐emptive group was half that of the bail‐out group. Additionally, the risk of both infectious and vascular complications was lower in the pre‐emptive group compared to the bail‐out tMCS strategy.Conclusion: We found that the timely implantation of tMCS in thoracic surgery—either to mitigate patients' heightened cardiovascular risk or as a rescue strategy in the event of life‐threatening surgical complications—may lead to better patient outcomes, as well as allowing them to undergo curative surgery with an acceptable safety profile, characterized by overall good survival rates and a low incidence of device‐related complications.
Background/Objective: Out-of-hospital cardiac arrest (OHCA) poses a substantial public health concern. A collective evaluation of clinical trials is crucial for understanding systemic trends and progress within a specific research area of interest, ultimately shaping future directions. We performed a comprehensive analysis of the characteristics of trials in the adult OHCA population registered on ClinicalTrials.gov. Methods: Aided by medical subject headings (MeSH), we systematically searched the ClinicalTrials.gov database. Trends over time were assessed with the Cochran–Mantel–Haenszel test. The association between publication year and annual number was assessed with the Pearson correlation coefficient. Results: Out of 152 trials spanning the 2003–2023 period, 29.6% were observational and 70.4% were interventional. Compared with the observational trials, interventional trials were more often randomized (RCT) and achieved full publication status in 84% of cases (p = 0.03). The primary focus of interventional trials was “procedures” (43%), “devices” (23%), and “drugs” (21%). Observational studies focused on “biomarkers” (16%) and “diagnostic test” (13%) (p < 0.001). A decrement in the number of interventional trials with a sample size ≥100 patients across three temporal study points was observed. Nevertheless, published studies predominantly had a sample size ≥100 patients (76%), in contrast to unpublished trials (p ≤ 0.001). An increase in the number of interventional studies funded by the “academic/university” sector was also recorded. Conclusions: Clinical trials on OHCA primarily involved interventions aimed at treatment and were more often randomized, single-center, with small (<100) sample sizes, and funded by the “academic/university” sector.